🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Out now in @JNCI_now (academic.oup.com/jnci/advance-a…)! @sloan_kettering H&N team’s work on Precision Radiotherapy for HPV+ HNSCC: **30Gy** for definitive treatment! Spear-headed by Nancy Lee & Eric Sherman, & and an all-star translational cast (JRF, SNP, TC, & more). #radonc #hncsm (1/N)

☢️Journal of Clinical Oncology: Of 152 analysable pts, 128 had nonhypoxic tumors & received 30Gy w chemo instead of SOC 70Gy. Hypoxia driven de-escalation to curative-intent CRT for HPV+ #hncsm oropharyngeal cancer found preserved efficacy & substantially reduced toxicity. ascopubs.org/doi/full/10.12…

👀 Check out what’s popular this week in #JCO: Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma 👉 brnw.ch/21wGqFa #OropharyngealCarcinoma #HPV #hncsm

We are constantly innovating our RT contouring for #headneckcancers #HPVOPC #NPC Another collaboration with a detailed atlas of how to reduce the target volumes for different T-cat in NPC. WIP to develop a new guideline for NPC RT planning! sciencedirect.com/science/articl…

Melvin LK CHUA | FRCR, PhD, FASCO Nadeem Riaz C. Jillian Tsai, MD, PhD Daniel Ma Regardless all phase 2 trials should lead to phase 3. Our FMISO 30 Gy work is leading to a phase 3 FDA registration trial, to be opened this summer.

Cannot wait to hear more details about this important trial. 4:45PM CDT! Percy Lee MD Puneeth Iyengar NRG Oncology Nadeem Riaz @JYangMDPhD Lawson Eng David Palma, MD, PhD

Mark Storey C. Jillian Tsai, MD, PhD Sana Karam, MD, PhD Sean McBride Nancy Lee I think two separate ideas are getting confused — 30gy definitive treatment using FMISO is not ready for routine practice and needs a phase 3 trial. Elective dosing with 30gy (when giving chemo) is a separate question and may be ready for prime time.

A very thoughtful opinion piece by Nancy Lee Memorial Sloan Kettering Radiation Oncology Lực Morris Max Diehn, MD/PhD outlining the caveats of using TTMV-HPV DNA as a routine biomarker for surveillance and treatment decision-making. Given the lack of robust sensitivity, such application should be carried out in

Our paper on a new approach to precision radiotherapy -- “Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy” led by Victor Ng and Sonali Sinha is out in Clinical Cancer Research #radonc #radbio (1/N) aacrjournals.org/clincancerres/…

FMISO PET is often criticized for having low signal-to-noise. Great work from Rick Wray MD & Heiko Schoeder shows that training can increase inter-reader agreement from a kappa of 0.34 to 0.86! An important step to move FMISO from research to clinic. jnm.snmjournals.org/content/early/…

Interested in hearing about a dosimetric analysis of 1904 3-fraction spine SBRT cases at Memorial Sloan Kettering Radiation Oncology to identify a new cord constraint to minimize risk of radiation myelitis after spine SBRT? Come to my talk at ASTRO on Sunday! Dan Higginson

Are spinal metastases from certain types of cancers more sensitive or more resistant to spine SBRT? Come to the quick pitch talk at ASTRO to find out more! Dan Higginson Memorial Sloan Kettering Radiation Oncology

Drew Moghanaki NRG Oncology Sana Karam, MD, PhD Corinne Faivre-Finn Not surprised. I’ve been preaching this for years based on Javelin HN100 results. There is a subset that will have benefit from IO, including large HN fields and fractionated RT. Nadeem Riaz knows who. Look for his work.

Brandon Imber presented on how radiation as a bridging therapy is particularly good at cytoreducing disease and improving outcomes with CAR T infusion #ASTRO24

C. Jillian Tsai, MD, PhD Sue Yom NRG Oncology ASTRO Nancy Lee I think one the big takeaways from HN 005 is that we need better prognostic criteria for deintensification. Possible candidate markers- Hypoxia, radiographic ENE, circulating DNA?

Very happy to share our latest work on pulmonary carcinoids published in Journal of Clinical Oncology: TERT Expression and Clinical Outcome in Pulmonary Carcinoids ascopubs.org/doi/10.1200/JC… Thanks to all involved! SFB1399 Department of Translational Genomics Uniklinik Köln Charlie Rudin Natasha Rekhtman MD PhD Matthieu Foll 🦋 @matthieufoll.bsky.social Alex Di Genova

📢 Just published in JCO! What is the optimal chemotherapy for oligodendroglioma patients? Our study using data from the national prospective cohort POLA found better PFS and OS outcomes with first-line RT/PCV compared to RT/TMZ ascopubs.org/doi/10.1200/JC…

MSK radiation oncologist Dr. Yao Yu discusses how MSK is using #protontherapy to further advance treatment of CNS tumors. This sophisticated treatment has recently proved effective in the treatment of #leptomeningealmetastases. bit.ly/3ZWS34s bit.ly/4eXci6j

🎉 Super excited to announce that our study "Colibactin-driven colon cancer requires adhesin-mediated epithelial binding" is now published in Nature! Huge congratulations to first authors Maude Jans and Magdalena Kolata for their fantastic work! 1/6🧵🎉 nature.com/articles/s4158…

Led by Drs. Zakeri & Nancy Lee, we report early Memorial Sloan Kettering Radiation Oncology exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% platinum, no uninvolved 1B+5 ☑️73 pts, f/u 23 months ✅no solitary elective failures, all LRF include 70 Gy failures ✅good QoL 👉 shorturl.at/CKA6W